A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
← catalyst calendarNCT07668336 · readout ≤ 1,319 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
170estimated
Sites
71
Countries
Belgium, Brazil, India +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Mar 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Orforglipron — also filed as LY3502970
- Drug: Dulaglutide — also filed as LY2189265
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Hemoglobin A1c (HbA1c)
measured Baseline, Week 40
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed